Needham & Company LLC Issues Positive Forecast for Trevi Therapeutics (NASDAQ:TRVI) Stock Price

Trevi Therapeutics (NASDAQ:TRVI) had its price objective lifted by Needham & Company LLC from $8.00 to $25.00 in a research report released on Monday, MarketBeat.com reports. The brokerage currently has a buy rating on the stock.

A number of other research firms also recently weighed in on TRVI. HC Wainwright increased their target price on shares of Trevi Therapeutics from $6.00 to $7.50 and gave the company a “buy” rating in a research report on Thursday, December 12th. D. Boral Capital reissued a “buy” rating and set a $21.00 target price on shares of Trevi Therapeutics in a research report on Friday. Seven equities research analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $14.56.

Trevi Therapeutics Stock Up 41.2 %

Trevi Therapeutics stock opened at $6.07 on Monday. Trevi Therapeutics has a twelve month low of $2.30 and a twelve month high of $7.39. The firm has a 50 day moving average price of $4.18 and a 200-day moving average price of $3.54. The company has a market capitalization of $466.58 million, a P/E ratio of -13.80 and a beta of 0.90.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the business. Summit Investment Advisors Inc. boosted its holdings in Trevi Therapeutics by 84.2% in the 4th quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company’s stock worth $26,000 after buying an additional 2,894 shares during the period. Bank of New York Mellon Corp boosted its holdings in Trevi Therapeutics by 2.1% in the 4th quarter. Bank of New York Mellon Corp now owns 140,219 shares of the company’s stock worth $578,000 after buying an additional 2,935 shares during the period. SG Americas Securities LLC boosted its holdings in Trevi Therapeutics by 14.5% in the 4th quarter. SG Americas Securities LLC now owns 26,792 shares of the company’s stock worth $110,000 after buying an additional 3,387 shares during the period. Invesco Ltd. boosted its holdings in Trevi Therapeutics by 21.2% in the 4th quarter. Invesco Ltd. now owns 23,621 shares of the company’s stock worth $97,000 after buying an additional 4,133 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its holdings in Trevi Therapeutics by 32.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 25,166 shares of the company’s stock worth $104,000 after buying an additional 6,119 shares during the period. 95.76% of the stock is owned by institutional investors.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.